347 related articles for article (PubMed ID: 32662804)
21. Keto form of curcumin derivatives strongly binds to Aβ oligomers but not fibrils.
Yanagisawa D; Kato T; Taguchi H; Shirai N; Hirao K; Sogabe T; Tomiyama T; Gamo K; Hirahara Y; Kitada M; Tooyama I
Biomaterials; 2021 Mar; 270():120686. PubMed ID: 33540171
[TBL] [Abstract][Full Text] [Related]
22. Retinal Levels of Amyloid Beta Correlate with Cerebral Levels of Amyloid Beta in Young APPswe/PS1dE9 Transgenic Mice before Onset of Alzheimer's Disease.
Mei X; Yang M; Zhu L; Zhou Q; Li X; Chen Z; Zou C
Behav Neurol; 2020; 2020():1574816. PubMed ID: 33029254
[TBL] [Abstract][Full Text] [Related]
23. Curcuminoid binds to amyloid-β1-42 oligomer and fibril.
Yanagisawa D; Taguchi H; Yamamoto A; Shirai N; Hirao K; Tooyama I
J Alzheimers Dis; 2011; 24 Suppl 2():33-42. PubMed ID: 21335654
[TBL] [Abstract][Full Text] [Related]
24. PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease.
Toyama H; Ye D; Ichise M; Liow JS; Cai L; Jacobowitz D; Musachio JL; Hong J; Crescenzo M; Tipre D; Lu JQ; Zoghbi S; Vines DC; Seidel J; Katada K; Green MV; Pike VW; Cohen RM; Innis RB
Eur J Nucl Med Mol Imaging; 2005 May; 32(5):593-600. PubMed ID: 15791432
[TBL] [Abstract][Full Text] [Related]
25. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
26. In Vivo Assessment of Retinal Biomarkers by Hyperspectral Imaging: Early Detection of Alzheimer's Disease.
More SS; Beach JM; McClelland C; Mokhtarzadeh A; Vince R
ACS Chem Neurosci; 2019 Nov; 10(11):4492-4501. PubMed ID: 31603648
[TBL] [Abstract][Full Text] [Related]
27. In vivo detection of amyloid β deposition using ¹⁹F magnetic resonance imaging with a ¹⁹F-containing curcumin derivative in a mouse model of Alzheimer's disease.
Yanagisawa D; Amatsubo T; Morikawa S; Taguchi H; Urushitani M; Shirai N; Hirao K; Shiino A; Inubushi T; Tooyama I
Neuroscience; 2011 Jun; 184():120-7. PubMed ID: 21497641
[TBL] [Abstract][Full Text] [Related]
28. Ube3a deficiency inhibits amyloid plaque formation in APPswe/PS1δE9 mouse model of Alzheimer's disease.
Singh BK; Vatsa N; Kumar V; Shekhar S; Sharma A; Jana NR
Hum Mol Genet; 2017 Oct; 26(20):4042-4054. PubMed ID: 29016862
[TBL] [Abstract][Full Text] [Related]
29. Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease.
Liu Y; Yoo MJ; Savonenko A; Stirling W; Price DL; Borchelt DR; Mamounas L; Lyons WE; Blue ME; Lee MK
J Neurosci; 2008 Dec; 28(51):13805-14. PubMed ID: 19091971
[TBL] [Abstract][Full Text] [Related]
30. [Development of SPECT Probes for In Vivo Imaging of β-Amyloid and Tau Aggregates in the Alzheimer's Disease Brain].
Watanabe H
Yakugaku Zasshi; 2017; 137(11):1361-1365. PubMed ID: 29093372
[TBL] [Abstract][Full Text] [Related]
31. Optical Imaging of Beta-Amyloid Plaques in Alzheimer's Disease.
Luo Z; Xu H; Liu L; Ohulchanskyy TY; Qu J
Biosensors (Basel); 2021 Jul; 11(8):. PubMed ID: 34436057
[TBL] [Abstract][Full Text] [Related]
32. Microglial Activation in the Retina of a Triple-Transgenic Alzheimer's Disease Mouse Model (3xTg-AD).
Salobrar-García E; Rodrigues-Neves AC; Ramírez AI; de Hoz R; Fernández-Albarral JA; López-Cuenca I; Ramírez JM; Ambrósio AF; Salazar JJ
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32012676
[TBL] [Abstract][Full Text] [Related]
33. Butyrylcholinesterase-knockout reduces fibrillar β-amyloid and conserves
DeBay DR; Reid GA; Macdonald IR; Mawko G; Burrell S; Martin E; Bowen CV; Darvesh S
Brain Res; 2017 Sep; 1671():102-110. PubMed ID: 28729192
[TBL] [Abstract][Full Text] [Related]
34. Ocular indicators of Alzheimer's: exploring disease in the retina.
Hart NJ; Koronyo Y; Black KL; Koronyo-Hamaoui M
Acta Neuropathol; 2016 Dec; 132(6):767-787. PubMed ID: 27645291
[TBL] [Abstract][Full Text] [Related]
35. Changes in the brain and plasma Aβ peptide levels with age and its relationship with cognitive impairment in the APPswe/PS1dE9 mouse model of Alzheimer's disease.
Izco M; Martínez P; Corrales A; Fandos N; García S; Insua D; Montañes M; Pérez-Grijalba V; Rueda N; Vidal V; Martínez-Cué C; Pesini P; Sarasa M
Neuroscience; 2014 Mar; 263():269-79. PubMed ID: 24447596
[TBL] [Abstract][Full Text] [Related]
36. Development of novel theranostic agents for in vivo amyloid imaging and protective effects on human neuroblastoma cells.
Li Y; Yan L; Cai J; Zhang W; Li L; Du Z; Dong C; Meunier B; Chen H
Eur J Med Chem; 2019 Nov; 181():111585. PubMed ID: 31404860
[TBL] [Abstract][Full Text] [Related]
37. Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study.
Rodriguez-Vieitez E; Ni R; Gulyás B; Tóth M; Häggkvist J; Halldin C; Voytenko L; Marutle A; Nordberg A
Eur J Nucl Med Mol Imaging; 2015 Jun; 42(7):1119-32. PubMed ID: 25893384
[TBL] [Abstract][Full Text] [Related]
38. Retinal hyperspectral imaging in the 5xFAD mouse model of Alzheimer's disease.
Lim JKH; Li QX; Ryan T; Bedggood P; Metha A; Vingrys AJ; Bui BV; Nguyen CTO
Sci Rep; 2021 Mar; 11(1):6387. PubMed ID: 33737550
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and evaluation of 1-(4-[¹⁸F]fluoroethyl)-7-(4'-methyl)curcumin with improved brain permeability for β-amyloid plaque imaging.
Lee I; Yang J; Lee JH; Choe YS
Bioorg Med Chem Lett; 2011 Oct; 21(19):5765-9. PubMed ID: 21885280
[TBL] [Abstract][Full Text] [Related]
40. Ocular amyloid imaging at the crossroad of Alzheimer's disease and age-related macular degeneration: implications for diagnosis and therapy.
Ong SS; Proia AD; Whitson HE; Farsiu S; Doraiswamy PM; Lad EM
J Neurol; 2019 Jul; 266(7):1566-1577. PubMed ID: 30155741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
